Search company, investor...

Predict your next investment

Corporation
HEALTHCARE | Disease Diagnosis
myriad.com

Investments

3

Portfolio Exits

3

Partners & Customers

10

Service Providers

1

About Myriad Genetics

Myriad Genetics is a molecular diagnostic company dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad offers an array of genetic tests, prognostic tests and personalized medicine tests to help healthcare providers assess a patient's increased cancer risk, disease aggressiveness and optimize efficacy of chemotherapy. Myriad's testing products can provide healthcare providers with information to help make medical management decisions to reduce cancer risk and help make sure specific treatments are tailored for each individual patient. It was founded in 1991 and is based in Salt Lake City, Utah.

Headquarters Location

320 Wakara Way

Salt Lake City, Utah, 84108,

United States

801-584-3600

Want to inform investors similar to Myriad Genetics about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Research containing Myriad Genetics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Myriad Genetics in 1 CB Insights research brief, most recently on Nov 11, 2020.

Latest Myriad Genetics News

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

Sep 19, 2023

Myriad Genetics Issues 2022 Environmental, Social and Governance Report September 19, 2023 at 07:01 am EDT Share SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social and Governance report, highlighting key efforts that reflect its commitment to conduct operations as a responsible, equitable and sustainable partner in the healthcare industry. “At Myriad, we understand the important role we play in advancing health equity and social justice,” said Paul Diaz, president and chief executive officer, Myriad Genetics. “We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. In our 2022 ESG report, we highlight how these topics are directly linked to our purpose and values, and share updates on our progress and plans to remain a transparent and accountable corporate citizen.” Key highlights from the report include: Advancing scientific research and patient care. Myriad is sharing data for use in clinical care and scientific research in several ways, such as hereditary cancer and prenatal data with ClinVar and hereditary cancer data with the California and Georgia SEER registries. Myriad also established the Precise Treatment Registry, which gives clinicians access to clinical insights across patient populations and the ability to explore hypotheses in real time. Broadening affordable access to genetic testing for all patient populations. In 2022, Myriad provided more than $31 million in financial assistance to 63,000+ uninsured and underinsured patients, offering financial assistance, free testing, and direct pay options to those in need. Progressing diversity, equity and inclusion efforts. Myriad is committed to recruiting, hiring and promoting team members from diverse backgrounds. At the end of 2022, women made up 62% of the Myriad workforce and 45% of leadership roles. Protecting our environment. Since 2019, Myriad has recycled approximately 102 tons of plastic from its Salt Lake City laboratories, including 31.4 tons of plastic during 2022. Myriad is working to bring its Labs of the Future online which will transform how it conducts operations and will significantly reduce its environmental footprint. For more information about Myriad’s ESG efforts, read the 2022 report About Myriad Genetics Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com. Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the company’s laboratories of the future will transform how it conducts operations and significantly reduce its environmental footprint. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on March 1, 2023, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. Media Contact:

Myriad Genetics Investments

3 Investments

Myriad Genetics has made 3 investments. Their latest investment was in RainDance Technologies as part of their Series E - II on March 3, 2014.

CBI Logo

Myriad Genetics Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/3/2014

Series E - II

RainDance Technologies

$16.5M

No

10

4/29/2013

Series E

Subscribe to see more

$99M

Subscribe to see more

10

9/9/2011

Debt

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/3/2014

4/29/2013

9/9/2011

Round

Series E - II

Series E

Debt

Company

RainDance Technologies

Subscribe to see more

Subscribe to see more

Amount

$16.5M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

10

10

10

Myriad Genetics Portfolio Exits

3 Portfolio Exits

Myriad Genetics has 3 portfolio exits. Their latest portfolio exit was Myriad Genetics - Autoimmune Unit on May 03, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/3/2021

Divestiture

Myriad Genetics - Autoimmune Unit

$99M

6

4/27/2021

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

1/16/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/3/2021

4/27/2021

1/16/2017

Exit

Divestiture

Divestiture

Acquired

Companies

Myriad Genetics - Autoimmune Unit

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

6

10

10

Myriad Genetics Acquisitions

6 Acquisitions

Myriad Genetics acquired 6 companies. Their latest acquisition was Gateway Genomics on November 01, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/1/2022

$99M

Acquired

3

5/29/2018

Series E+

Subscribe to see more

$99M

$99M

Subscribe to see more

10

8/4/2016

Series D

Subscribe to see more

$99M

$99M

Subscribe to see more

10

5/31/2016

Grant

Subscribe to see more

$99M

$99M

Subscribe to see more

10

2/5/2014

Series D

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

11/1/2022

5/29/2018

8/4/2016

5/31/2016

2/5/2014

Investment Stage

Series E+

Series D

Grant

Series D

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Myriad Genetics Partners & Customers

10 Partners and customers

Myriad Genetics has 10 strategic partners and customers. Myriad Genetics recently partnered with Onsite Women’s Health on August 8, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

8/22/2023

Partner

United States

Myriad Genetics and Onsite Women's Health Partner to Help More Women Understand Breast Cancer Risk

This press release contains `` forward-looking statements '' within the meaning of the Private Securities Litigation Reform Act of 1995 , including statements relating to the benefits of the new breast cancer risk assessment program , including that it will increase access to genetic testing and help identify and screen younger patients who are at an increased risk for breast cancer , and that the program will be offered to one third of Onsite 's OBGYN and PCP partnerships in the coming months , with further expansion expected in 2024 .

4

6/14/2023

Partner

United States

By Gwendolyn Turner, VP of Diversity, Equity & Inclusion, and Learning & Development. Myriad Genetics Blog > We’re Teaming Up with the March of Dimes to Support Moms and Babies.

Myriad Genetics is excited to team up with the March of Dimes , which has spent decades taking on the grassroots activities needed to build strong relationships in communities where help is needed most .

1

6/12/2023

Partner

United States

Myriad Partners With MD Anderson to Study MRD Testing in Renal Cell Carcinoma

NEW YORK -- Myriad Genetics on Monday said it is starting a new collaboration with MD Anderson Cancer Center to develop Myriad Genetics 's minimal residual disease testing platform as a tool to guide treatment , surveillance , and radiotherapy response in patients with metastatic renal cell carcinoma .

1

4/18/2023

Partner

United States

Subscribe to see more

Subscribe to see more

10

4/12/2023

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

8/22/2023

6/14/2023

6/12/2023

4/18/2023

4/12/2023

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

Myriad Genetics and Onsite Women's Health Partner to Help More Women Understand Breast Cancer Risk

This press release contains `` forward-looking statements '' within the meaning of the Private Securities Litigation Reform Act of 1995 , including statements relating to the benefits of the new breast cancer risk assessment program , including that it will increase access to genetic testing and help identify and screen younger patients who are at an increased risk for breast cancer , and that the program will be offered to one third of Onsite 's OBGYN and PCP partnerships in the coming months , with further expansion expected in 2024 .

By Gwendolyn Turner, VP of Diversity, Equity & Inclusion, and Learning & Development. Myriad Genetics Blog > We’re Teaming Up with the March of Dimes to Support Moms and Babies.

Myriad Genetics is excited to team up with the March of Dimes , which has spent decades taking on the grassroots activities needed to build strong relationships in communities where help is needed most .

Myriad Partners With MD Anderson to Study MRD Testing in Renal Cell Carcinoma

NEW YORK -- Myriad Genetics on Monday said it is starting a new collaboration with MD Anderson Cancer Center to develop Myriad Genetics 's minimal residual disease testing platform as a tool to guide treatment , surveillance , and radiotherapy response in patients with metastatic renal cell carcinoma .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

1

1

10

10

Myriad Genetics Service Providers

1 Service Provider

Myriad Genetics has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acquired

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Myriad Genetics Team

21 Team Members

Myriad Genetics has 21 team members, including , .

Name

Work History

Title

Status

Dennis B. Farrar

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Dennis B. Farrar

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Myriad Genetics to Competitors

Genomic Expression Logo
Genomic Expression

Genomic Expression's mission is to save lives and to make the delivery of healthcare more effective. The company helps doctors select the best drug for their patients, by leveraging it's clinically focused RNA sequencing technology called OneRNA. OneRNA can uniquely identify and quantify more than 34,000 RNA's in one assay and is currently undergoing beta testing by pharma companies and clinicians. Preliminary data suggests that the OneRNA assay may be suitable for determining response to the novel immune therapies including the PD1 checkpoint inhibitors.

Agendia Logo
Agendia

Agendia is a privately held, leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer and colorectal cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Our offerings include the FDA-cleared MammaPrint FFPE as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable breast cancer biology, and TargetPrint, a breast cancer ER/PR/HER2 expression assay. These tests can help physicians assess a patient's individual risk for metastasis – that is, which patients are more sensitive to chemo, hormonal, or combination therapy, and which patients may not require these treatments and which patients may be treated with other, less arduous and costly methods.

Perthera Logo
Perthera

Perthera uses AI to analyze patient medical and molecular data to enable hospitals, physicians & advocacy groups to deliver personalized cancer care. The Perthera Platform matches patients to ranked therapeutic options to improve their clinical outcomes and allows patient data access to the key segments in the Precision Oncology market. It was founded in 2012 and is based in McLean, Virginia.

Strata Oncology Logo
Strata Oncology

Strata Oncology is a precision medicine company that provides no-cost tumor sequencing to advanced cancer patients and a portfolio of matching clinical trials.

G
Genecast

Genecast develops cancer diagnostic products. It offers a cancer screening kit that helps to diagnose and monitor cancer through liquid biopsy using its Allele-Discriminating Priming System (ADPS) technology. The company was founded in 2016 and is based in Seoul, South Korea.

D
DxTerity Diagnostics

DxTerity Diagnostics is a biotechnology company focused on utilizing the NEAT platform to provide a pathway to incorporate genetic testing and complex gene signatures into routine medical care.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.